Quotation of the Day: On the value of a schedule
“I write only when inspiration strikes. Fortunately it strikes every morning at nine o’clock sharp.” W. Somerset Maugham
Links
Three parent baby? Area Deprivation Index only reflects median home price? Organ on a chip? Using the “uptrend effect” to increase rates of exercise. Cognitive activity at work and the risk of dementia
Healthcare Economist on Marketplace
What are the economic consequences of the updated USPSTF recommendations to move the age for annual breast cancer screening to age 40? I was interviewed at NPR’s Marketplace Morning Report today (May 11, 2023) to help answer the question. You can listen to the episode here (the segment on breast cancer screening starts at 5:32).…
Quotations of the Day: ISPOR Edition
As heard at ISPOR 2023 in Boston: On high US drug prices: “My hope as a European is that US never gets its health system in order.” And his Yoda-like pronouncement: “Affordability is important; but value is critical” Michael Drummond HT: Peter Neumann. See also Dr. Neumann’s ISPOR recap thread
European Union Pharmaceutical Package: A Summary
Today I’m turning this post over to some of my FTI colleagues in Europe (Antoine Mialhe, Katja Murray and Valeria Fagone among others) who helped summarize the Reform of the EU pharmaceutical legislation that the European Union (EU) adopted on April 26, 2023. The summary below is provided by the FTI Consulting team in Brussels…
How long were US schools closed during COVID-19 compared to other countries?
Results below from UNESCO data. Presented without commentary. HT: Marginal Revolution
ISPOR 2023
If you’re attending the ISPOR 2023 conference in Boston, MA please feel free to come by view some of my research. This includes the following: Podium Presentation #108: Economic Evaluations of Rare Diseases: “Quantifying the Insurance and Altruism Value for Rare Diseases: A Case Study for Duchenne Muscular Dystrophy”. Jason Shafrin will be presenting this work as…
Links
Impact of retirement on health. JAMA articles on physician use of AI (1, 2, 3) Is the COVID-19 emergency over? What EHR reforms are needed? Pharma vs. PBM: patients lose out?
A Strategy For Value-Based Drug Pricing Under The Inflation Reduction Act
This is the title of my Health Affairs Forefront article published today alongside co-authors Darius Lakdawalla, Jalpa Doshi, Louis Garrison, Anup Malani, Peter Neumann, Charles Phelps, Adrian Towse, and Richard Willke. The article begins by discussing some of the pros and cons of different approaches for CMS to set the maximum fair price (MFP). Across…
Quantifying 21st-Century Opportunity Costs of FDA Regulation
That is the title of a very interesting paper by Casey Mulligan (2023) [NBER WP version]. The full title includes the phrase “Peltzman revisited”. This refers to a paper by Peltzman (1973).When speaking of the 1962 “Drug Efficacy Amendment” (EA) to the Federal Food, Drug, and Cosmetic Act a key piece of research was Peltzman…